Literature DB >> 826923

A mass fragmentographic method for the determination of chlorpromazine and two of its active metabolites in human plasma and CSF.

G Alfredsson, B Wode-Helgodt, G Sedvall.   

Abstract

A mass fragmentographic method for the quantitation of chlorpromazine (CPZ), mono-demethyl-chlorpromazine (nor1-CPZ), and 7-hydroxy-chlorpromazine (7-OH-CPZ) in plasma, cerebrospinal fluid, and tissues has been developed. The deuterated analogues of the compounds are used as internal standards. The high specificity was ascertained by multiple ion determination. The experimental error is below 10%. The sensitivity allows determination of sub ng quantities of CPZ per ml cerebrospinal fluid. The method has been applied to the analysis of drug concentrations in plasma and cerebrospinal fluid (CSF) of chlorpromazine-treated patients. The amount of CPZ in CSF was about 3% of the plasma level. The CPZ levels in plasma and CSF were significantly correlated.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 826923     DOI： 10.1007/BF00423250

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  12 in total

1.  Development of radioimmunoassay for chlorpromazine.

Authors:  K Kawashima; R Dixon; S Spector
Journal:  Eur J Pharmacol       Date:  1975 Jun-Jul       Impact factor: 4.432

2.  Red blood cell drug binding as a possible mechanism for tranquilization.

Authors:  A A Manian; L H Piette; D Holland; T Grover; F Leterrier
Journal:  Adv Biochem Psychopharmacol       Date:  1974

3.  Relation between binding to plasma protein, apparent volume of distribution, and rate constants of disposition and elimination for chlorpromazine in three species.

Authors:  S H Curry
Journal:  J Pharm Pharmacol       Date:  1972-10       Impact factor: 3.765

4.  Quantitation of chlorpromazine and its metabolites in human plasma and urine by direct spectrodensitometry of thin-layer chromatograms.

Authors:  T L Chan; G Sakalis; S Gershon
Journal:  Adv Biochem Psychopharmacol       Date:  1974

5.  Chlorpromazine metabolism. V. Disposition of free and conjugated metabolites in blood fractions of schizophrenic patients.

Authors:  P N Kaul; M K Ticku; M L Clark
Journal:  J Pharm Sci       Date:  1972-11       Impact factor: 3.534

6.  Effect of chlorpromazine and some of its metabolites on synthesis and turnover of catecholamines formed from 14 C-tyrosine in mouse brain.

Authors:  H Nybäck; G Sedvall
Journal:  Psychopharmacologia       Date:  1972

7.  Chlorpromazine metabolism in sheep. II. In vitro metabolism and preparation of 3 H-7-hydroxychlorpromazine.

Authors:  L G Brookes; M A Holmes; I S Forrest; V A Bacon; A M Duffield; M D Solomon
Journal:  Agressologie       Date:  1971

8.  Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromatography with an electron capture detector.

Authors:  S H Curry
Journal:  Anal Chem       Date:  1968-07       Impact factor: 6.986

9.  Effect of chlorpromazine and some of its metabolites on the dopamine-sensitive adenylate cyclase of rat brain striatum.

Authors:  R J Miller; L L Iversen
Journal:  J Pharm Pharmacol       Date:  1974-02       Impact factor: 3.765

10.  The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics.

Authors:  A V Mackay; A F Healey; J Baker
Journal:  Br J Clin Pharmacol       Date:  1974-10       Impact factor: 4.335
View more
  9 in total

1.  HPLC with electrochemical detection to measure chlorpromazine, thioridazine and metabolites in human brain.

Authors:  C N Svendsen; E D Bird
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 2.  Plasma level monitoring of antipsychotic drugs.

Authors:  T B Cooper
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

3.  Levels of chlorpromazine and its active metabolites in rat brain and the relationship to central monoamine metabolism and prolactin secretion.

Authors:  G Alfredsson; F A Wiesel; P Skett
Journal:  Psychopharmacology (Berl)       Date:  1977-06-06       Impact factor: 4.530

4.  Plasma protein binding of perazine and amitriptyline in psychiatric patients.

Authors:  M Brinkschulte; H J Gaertner; H W Schied; U Breyer-Pfaff
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients--relationship to drug concentrations.

Authors:  G Alfredsson; C Härnryd; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  The presence of 7-hydroxychlorpromazine in CSF of chloropromazine-treated patients.

Authors:  G Alfredsson; M Lindberg; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

7.  Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients--relationship to drug concentrations.

Authors:  G Alfredsson; C Härnryd; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography.

Authors:  G Wik; F A Wiesel; I Sjögren; G Blomqvist; T Greitz; S Stone-Elander
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

9.  Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses.

Authors:  B Wode-Helgodt; G Alfredsson
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.